Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
Venlo,NL (ots Ad hoc-Service) - Karen Hedine General Manager
QIAGEN Genomics, Inc. (425)398-3140
Peer M. Schatz Chief Financial Officer QIAGEN N.V.
Noonan/Russo Communications, Inc. Mary Claire Bice (212)696-4455
AGILENT AND QIAGEN GENOMICS ENTER INTO SNP GENOTYPING AGREEMENT
This significant Alliance links Agilent's leading position in mass
spectrometry with QIAGEN Genomics' technologies and MasscodeTM
Agilent Technologies, Inc. (NYSE: A), a leading vendor of
communications and life sciences solutions and QIAGEN Genomics, Inc.,
a wholly-owned subsidiary of QIAGEN N.V. (Nasdaq: QGENF, Frankfurt
Neuer Markt: QIA; EASDAQ: QGEN), today announced that they have
entered into an exclusive value-added reseller agreement. The
agreement intends to leverage Agilent's single-quadrupole LC/MS with
QIAGEN Genomics' Masscode technologies and consumables to provide
single nucleotide polymorphism (SNP) genotyping systems to be
marketed by QIAGEN Genomics. In the second phase of the agreement,
both companies will jointly develop new Masscode tag chemistry and
mass spectrometry instrumentation solutions for SNP discovery,
proteomics and other applications.
Agilent, a market and technology leader in single quadrupole mass
spectrometry further agreed to exclusively optimize its mass
spectrometry systems for use with QIAGEN Genomics' MasscodeTM
technologies for SNP-genotyping. Under the terms of the agreement,
QIAGEN Genomics will exclusively promote its MasscodeTM technologies
on Agilent's systems. The parties are committed to devise and develop
applications of their technologies that will be used by
pharmaceutical companies to develop better drugs and to advance
disease discovery and pharmacogenetic research. Financial details of
the deal were not disclosed.
QIAGEN Genomics is a market and technology leader in genotyping
technologies. The company and its clients use single quadrupole mass
spectrometer instrumentation, MasscodeTM tags as well as other QIAGEN
technologies for cost effective high throughput SNP genotyping with
highest data quality standards.
Certain of the statements contained in this news release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's, QIAGEN Genomics' and Agilent's technologies, services,
products and markets and operating results are forward-looking, such
statements are based on current expectations that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with the challenges in
integrating newly-acquired businesses into QIAGEN's operations,
management of growth and international operations (including the
effects of currency fluctuations), variability of operating results,
the adoption and integration of new technologies, products and
services, the commercial development of the DNA sequencing and
genomics market, proteomics market, nucleic acid-based molecular
diagnostics market, and genetic vaccination and gene therapy markets,
competition, rapid or unexpected changes in technologies,
fluctuations in demand for genomics services (including seasonal
fluctuations), difficulties in successfully developing the companies'
technologies, services and products and combining these into
integrated solutions and providing such products and services, the
companies' ability to identify and develop new products and services
and to differentiate their products and services from competitors.
For further information pertinent to QIAGEN and QIAGEN Genomics refer
to the discussion in reports that QIAGEN has filed with the U.S.
Securities and Exchange Commission (SEC).
End of Message
Original-Content von: Qiagen N.V., übermittelt durch news aktuell